Biotechnology
Chinese Vaccine Biotech Ab&B Files for IPO, Drawing Attention from GSK, Merck, and Pfizer
Ab&B Bio-Tech, IPO, Chinese vaccine biotech, GSK, Merck, Pfizer, biotechnology, pharmaceutical industry
Neomorph Secures Third Major Collaboration with AbbVie for Molecular Glue Degraders Worth Up to $1.64 Billion
Neomorph, AbbVie, molecular glue degraders, protein degradation, oncology, immunology, biotechnology, pharmaceutical collaboration
Chinese Biotechs Flock to Hong Kong IPOs for Next Growth Phase
Chinese biotechs, Hong Kong IPOs, biotechnology, pharmaceuticals, listing reforms, HKEX, Chapter 18A, biotech listings, Greater Bay Area.
Numab Therapeutics Secures Additional $55 Million in Series C Funding to Advance Multi-Specific Antibody Therapies
Numab Therapeutics, Series C Funding, Multi-Specific Antibodies, Immunotherapy, Oncology, Inflammation, Biotechnology
Astellas Terminates Development of Autologous Cell Therapy for Lymphoma Following Pipeline Review
Astellas, lymphoma, CAR-T cell therapy, autologous cell therapy, pipeline review, cancer treatment, biotechnology
Velia Therapeutics Closes Operations, Remains Committed to Microprotein Therapeutic Potential
Velia Therapeutics, microproteins, biotechnology, therapeutic potential, company closure
Revance Therapeutics Faces Competing Buyout Offers: Teoxane SA Outbids Crown Laboratories
Revance Therapeutics, Teoxane SA, Crown Laboratories, buyout offers, merger agreement, biotechnology, skincare industry
Biopharmaceutical Manufacturing and Emerging Trends in 2024: A Global Outlook
Biopharmaceutical manufacturing, 2024 trends, personalized medicine, AI-driven drug discovery, biosimilars, cell and gene therapies, biotechnology innovations.
KdT Ventures Launches New Biotech Startup to Develop NGM Bio’s Rare Disease Drug Candidate NGM313
KdT Ventures, NGM Bio, NGM313, Rare Disease, Biotechnology, Drug Development, Phase 2 Trial
Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema
Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development